Background. Measurement of cardiac norepinephrine spillover may indicate the amount of transmitter at neuroeffector sites but does not distinguish neuronal release or reuptake in determining this amount or provide information about other aspects of sympathetic function. This report examines how cardiac spillover of the norepinephrine metabolite dihydroxyphenylglycol (DHPG) provides additional distinct information about cardiac sympathetic function.
B ecause of the importance of the sympathetic nervous system in the regulation of cardiovascular performance in stress and disease, investigators have long sought experimental approaches to assess sympathetic activity in clinical settings. The introduction of sensitive and specific techniques to measure plasma concentrations of norepinephrine, the principal neurotransmitter of sympathetic nerves, appeared to herald the end of this quest.1'2 Development of radiotracer techniques to estimate spillover of norepinephrine into plasma from specific tissues provided a traneuronally or spills over into plasma. The influences of these processes on norepinephrine turnover are weakened by the additional contribution from metabolism of norepinephrine leaking from vesicles, a process independent of exocytotic transmitter release. [8] [9] [10] [11] [12] Recognition that there is more to assessment of sympathetic function than measurement of sympathetic activity and that measurements of nerve traffic or norepinephrine spillover provide limited information indicates a need for additional approaches to assess sympathetic nervous function.
Dihydroxyphenylglycol (DHPG) is almost exclusively produced within sympathetic nerves from metabolism of norepinephrine leaking from storage vesicles or recaptured after exocytotic release. [8] [9] [10] [11] [12] The sympathetic nerves of the heart produce large amounts of DHPG; this is reflected by much higher concentrations of DHPG in coronary venous plasma than in arterial plasma.8 Therefore, measurement of the cardiac production of DHPG may be particularly appropriate for providing regional information about the turnover, reuptake, and intraneuronal disposition of norepinephrine in the heart. This report is based on data derived from cardiac catheterization studies of norepinephrine spillover at two centers. Assays of plasma DHPG were also carried out to ascertain whether cardiac spillovers of this catechol may provide additional information about sympathetic function. In some subjects, the neuronal uptake-blocking drug desipramine was administered to determine the proportion of cardiac DHPG production derived from norepinephrine recaptured by cardiac sympathetic nerves. The influence of sympathetic activation on the cardiac spillover of DHPG was examined before and during mental stress, intravenous yohimbine, isometric handgrip exercise, and cycling exercise. Cardiac spillovers of the catecholamine precursor dihydroxyphenylalanine (DOPA) and of the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were also examined to provide additional information about cardiac norepinephrine synthesis.
Methods

Patients
Fifty-seven patients, 41 at the Baker Medical Research Institute (BMRI), Victoria, Australia, and 16 at the National Institutes of Health (NIH), Bethesda, Md., underwent cardiac catheterization and received intravenous infusions of [3H]norepinephrine. At the BMRI, subjects included 35 normal volunteers and six patients with left ventricular heart failure. At the NIH, subjects included four patients with hypertrophic cardiomyopathy, five patients with microvascular angina diagnosed according to previously defined criteria,13 and seven with chest pain and normal coronary angiograms. All procedures were approved by the appropriate institutional review committees, and all patients gave written informed consent before studies began.
Catheterization
A coronary sinus thermodilution catheter used to measure coronary blood flow and sample coronary tients at the BMRI) or the right internal jugular vein (in patients at the NIH) and passed using fluoroscopic guidance into the coronary sinus. In patients at the NIH, the tip of the catheter was passed distally to the great cardiac vein. Correct positioning of the catheter was confirmed by manual injection of radiopaque contrast dye. Coronary venous blood samples were obtained simultaneously with samples taken from a radial or brachial artery by using a percutaneously placed cannula. The arterial cannula was also used to monitor systemic arterial pressure. An indwelling cannula in the antecubital or brachial vein was used for infusion of [3Hlnorepinephrine.
Radiotracer Infusion
At the NIH, [3H] norepinephrine (L-[2,5,6-3HJnor-epinephrine; New England Nuclear, Boston, Mass.) was prepared for human use in 50-,Ci aliquots and stored at -70°C until used. For each study, a 50-,uCi aliquot was diluted in 5% dextrose and infused at 1.25 ,uCi/min (1.5 ml/min). At the BMRI, [3H]norepinephrine (L- [7-3H] norepinephrine; New England Nuclear) was prepared for human use in 50-100-,uCi aliquots and stored in 0.05 M acetic acid at -70°C until used. For each study, an aliquot was diluted in 0.9% saline and 1 mM ascorbic acid and infused intravenously at 0.8 gCi/min (0.2 ml/min). The stability, purity, and preparation of radiotracers at both centers has been described in greater detail elsewhere. 14 
General Procedure
Subjects were studied in the morning after an overnight fast, having refrained from coffee and tobacco for at least 8 hours. All studies were performed in the supine position. Samples of arterial and coronary venous blood (8-10 ml) were collected simultaneously during infusions of [3H]norepinephrine, which in some subjects lasted up to 4 hours, but which in most subjects were terminated within 3 hours. A total of 235 pairs of arterial and coronary venous blood samples were collected from the 57 subjects included in this report.
Blood samples were stored on ice, and plasma was separated by centrifugation at 4°C and stored at -70°C until assayed for catechol content.
To examine for the effects of the length of the radiotracer infusion on cardiac production of [3H]DHPG, data from 203 paired arterial and coronary venous plasma samples (patients with cardiac failure or hypertrophic cardiomyopathy excluded) were partitioned into 20-minute time periods according to the time after the start of the radiotracer infusion at which samples were collected. The time of collection varied between 15 and 224 minutes after the start of the radiotracer infusion. At least two and up to eight pairs of blood samples were taken from each subject. Samples included those collected before and after the procedures described below. Some patients participated in up to three successive procedures; handgrip exercise and mental stress were carried out initially in random order, and cycling or intravenous infusion of desipramine were always carried out last. Each intervention period was preceded by a rest period of at least 15 minutes, at the end of which baseline arterial and coronary venous venous blood was inserted via a forearm vein (in pablood samples were taken.
Mental Arithmetic
In this procedure described in detail elsewhere,15 34 normal subjects at the BMRI performed mental arithmetic over 10 minutes by serial subtractions of a range of numbers from large numbers. Subjects were verbally encouraged to perform and were distracted by frequent interruptions. Blood samples were taken during the last minute of the procedure.
Isometric Handgrip Exercise
Fifteen normal volunteers studied at the BMRI performed isometric handgrip exercise (Harpenden Hand Grip, British Indicators, UK) at 20-30% of maximum strength for as long as possible up to 10 minutes. Blood samples were taken during the last minute of the exercise, which varied between 6 and 10 minutes.
Cycling Exercise
Nine normal volunteers studied at the BMRI performed cycling exercise in the supine position for 10 minutes at 50% of their maximum work capacity, according to a procedure described previously and shown to cause marked increases in cardiac norepinephrine spillover. 16 Blood samples were taken at the end of exercise.
Yohimbine Administration
At the NIH, yohimbine was administered intravenously to four patients with hypertrophic cardiomyopathy and seven with chest pain syndromes (four with microvascular angina and three with normal coronary angiograms). Yohimbine was administered initially as a 62.5 jig/kg intravenous bolus followed by a 15-minute infusion at 0.5 ,ug/kg/min; after absence of ill effects to the preliminary dose, another 62.5-,ug/kg bolus was given followed by a 15-minute infusion at 1 ,ug/kg/min. The cumulative dose has been previously established to increase plasma norepinephrine significantly.9 Blood samples were taken 15 minutes after the start of the 1 ,ug/kg/min infusion.
Desipramine Administration
In nine normal subjects and six patients with heart failure studied at the BMRI, desipramine was infused into a forearm vein at 10-20 jig kg-lmin-m. Infusions of desipramine started between 100 and 199 minutes after the start of radiotracer infusions (mean, 157 minutes).
Infusions lasted [25] [26] [27] [28] [29] [30] minutes, so that the total dose of desipramine administered was 0.25-0.5 mg/kg. Blood samples were taken at the end of the infusion.
Assay of Plasma Catechols and Metabolites
Catechols (norepinephrine, DHPG, DOPA, and DOPAC) were extracted from 1 ml plasma with alumina adsorption, separated by liquid chromatography according to previously described methods, and amounts were quantified by electrochemical detection. 17 were not corrected for the contribution from the exogenous ['HI-labeled catechols. Intra-assay and interassay coefficients of variation for the assays at both centers have been described previously. '7"18 Plasma concentrations of HVA in arterial and coronary venous plasma were estimated by using liquid chromatography with electrochemical detection according a method developed at the BMRI. 19 The intra-assay coefficient of variation for this assay was 2.8% (n =8), and the interassay coefficient of variation was 8.1% (n=23).
Data Analysis
The substantial extraction of norepinephrine during its passage through the coronary circulation.
Cardiac Spillovers of Catechols
In normal subjects at rest (n=34, BMRI subjects) cardiac spillover of DHPG averaged 601+±41 pmol/min, much more than the cardiac spillovers of norepinephrine, DOPA, or DOPAC (Table 2 ). Cardiac spillover of DHPG increased (p<0.01) by 35+10% during mental stress, by 31±9% after intravenous yohimbine, and by (DHPG) , and dihydroxyphenylalanine (DOPA) were measured in 42 normal subjects studied at the Baker Medical Research Institute (BMRI), Victoria, Australia, and the National Institutes of Health (NIH), Bethesda, Md. In 35 of these subjects (all at the BMRI), measurements of plasma dihydroxyphenylacetic acid (DOPAC) were carried out, and in 13 of these, measurements of plasma homovanillic acid (HVA) were also carried out. Plasma concentrations of 3-methoxy-4-hydroxyphenylglycol (MHPG) represent those reported in a previous study at the NIH for 10 patients with chest pain but normal coronary arteries.24 *p<0.002, significant arterial-venous increment. Results represent mean-+±SEM spillovers (pmol/min) determined in 34 normal subjects studied at the Baker Medical Research Institute, Victoria, Australia. Multiple determinations were made at rest in each subject so that mean spillovers for the group were determined from averaged spillovers in each subject.
178+±38% during cycling exercise, whereas isometric exercise was without effect (Figure 2 ). All stimuli increased (p<0.005) cardiac norepinephrine spillover (Table 3 ). Percentage increases in the cardiac spillover of norepinephrine were larger (p<0.001) than those in DHPG; therefore the ratio of DHPG to norepinephrine spillover decreased during sympathetic activation. During cycling exercise, the most potent stimulus, absolute increases in cardiac DHPG spillover were two thirds those of norepinephrine, whereas percentage increases were one tenth; therefore cardiac spillover of norepinephrine approached that of DHPG.
Relations Between Cardiac Spillovers of Dihydroxyphenylglycol and Norepinephrine
In normal subjects, there was no relation between cardiac spillovers of DHPG and norepinephrine at rest, whereas there was a positive relation (r=0.71,p<0.001) during sympathetic activation (Figure 3 ). The increase in cardiac DHPG spillover during sympathetic activation was also positively correlated (r=0.77, p<0.001) with the increase in norepinephrine spillover. The slopes of the linear regression lines describing the relations between cardiac DHPG and norepinephrine spillovers during sympathetic activation (y=0.65x+629) or the increase in cardiac DHPG and norepinephrine spillovers (y=0.64x+74) indicated that for every 1-pmol/min increase in the rate of cardiac norepinephrine spillover, there was a 0.64-0.65-pmol/min increase in the rate of cardiac DHPG spillover. (6 .5%) calculated in normal subjects by using the y-intercept of the relation between time of radiotracer infusion and the specific activity of [3H]DHPG produced by the heart (Figure 4, lower panel) .
In contrast to the partial but significant inhibitory effect of desipramine on cardiac production of [3H]-labeled DHPG, the cardiac spillover of endogenous DHPG was not significantly different before (802±120 pmol/min) and after (690±81 pmol/min) desipramine ( Figure 5, lower panel) .
Discussion
Disordered sympathetic nervous function is associated with several diseases of the heart, but in most instances, the exact nature of the abnormality is ill defined. Measurements of cardiac norepinephrine spillover may point to an abnormality in the amount of transmitter present at myocardial neuroeffector sites but cannot distinguish altered neuronal release from a difference in removal by neuronal reuptake or provide information about other aspects of sympathetic function. The present report highlights how cardiac sympathetic function may be examined more comprehensively by combined measurements of cardiac spillovers of DHPG and norepinephrine than by the latter alone.
Consistent and substantial arterial-venous increments in plasma DHPG across the coronary circulation ( Figure 1 ) and the eightfold greater cardiac spillover of DHPG than of norepinephrine (Table 2 ) illustrate the importance of local deamination as a major determinant of norepinephrine turnover. DHPG may be 0-methylated to 3-methoxy-4-hydroxyphenylglycol (MHPG), the other major cardiac norepinephrine metabolite.24 27 An arterial-venous increment in plasma MHPG across the human heart, 54% that of DHPG,24 indicates as in rats, cats, and rabbits25-27 that DHPG is also the principal cardiac norepinephrine metabolite in humans. Thus, combined cardiac spillover of norepinephrine and its deaminated metabolites, most notably DHPG, better reflects local transmitter turnover than does cardiac norepinephrine spillover alone.
DHPG is produced by intraneuronal metabolism of norepinephrine after either leakage of transmitter into the axoplasm from storage vesicles or reuptake of transmitter after exocytotic release; the contribution of the latter process is reflected by the decrease in DHPG production after neuronal uptake blockade.9"1 In the present study, adequacy of the dose of desipramine to inhibit norepinephrine reuptake was confirmed by the 71% decrease in cardiac ['H]norepinephrine extraction ( Figure 5 ). The insignificant decrease in cardiac spillover of endogenous DHPG after desipramine indicates that at rest, little of the DHPG produced by the heart is from recaptured norepinephrine. Thus, the major determinant of DHPG production and norepinephrine turnover in the human heart at rest is leakage of transmitter from vesicles. The inference from the above that exocytotic transmitter release makes a minimal contribution to cardiac DHPG production and norepinephrine turnover at rest is supported by the lack of relation between resting cardiac spillovers of norepinephrine and DHPG; however, their positive relation during sympathetic activation illustrates how the contribution of exocytotic norepinephrine release to DHPG production becomes more important as more norepinephrine is released (Figure 3) .
The partial contribution of exocytotic norepinephrine release to DHPG production was also reflected by the different proportional increases in cardiac spillovers of norepinephrine and DHPG during sympathetic activation (Table 3) . During cycling exercise, cardiac norepinephrine spillover increased 24-fold, substantially more than the 2.4-fold increase in DHPG spillover and the 5.4-fold increase in combined DHPG and norepinephrine spillover, illustrating considerable divergence between neuronal turnover and exocytotic release of norepinephrine. Thus, compared with norepinephrine spillover, cardiac spillover of DHPG is an indirect and insensitive index of exocytotic norepinephrine release but provides other information that cannot be provided by measurements of norepinephrine, including the extensive contribution of vesicular leakage to norepinephrine turnover. This extensive contribution enables stores of norepinephrine to be maintained during sympathetic activation by percentage increases in norepinephrine synthesis much smaller than those in exocytotic transmitter release; thus, during cycling exercise, a 5.4-fold increase in the rate of norepinephrine synthesis would be sufficient to offset the depletion in cardiac transmitter stores associated with the 24-fold increase in norepinephrine spillover.
The above considerations are relevant to interpretation of measurements of norepinephrine turnover using the disappearance of cardiac tissue stores of radioactive norepinephrine.28,29 To draw valid inferences from these measurements about sympathetic activity, it is necessary to isolate the contributions of exocytotic release and vesicular leakage of norepinephrine to transmitter turnover.
In view of findings that inhibition of neuronal uptake with desipramine blocked sympathetic activation-induced increases in cardiac DHPG production in dogs8 and arterial plasma DHPG in humans9'10 and rabbits,30 it appears likely that increased cardiac spillover of DHPG during mental arithmetic, intravenous yohimbine, and cycling exercise (Figure 2 ) in the present study was secondary to an increase in the amount of recaptured transmitter available for intraneuronal metabolism. Thus, the slope of the relation between cardiac spillovers of DHPG and norepinephrine during sympathetic activation (Figure 3 ) indicated that the amount of DHPG appearing in plasma from recaptured norepinephrine was 65% the amount of norepinephrine escaping local removal to spillover into plasma. This indicated that at rest, when norepinephrine spillover averaged 78±10 pmol/min, cardiac DHPG spillover derived from recaptured transmitter was 51 pmol/min. This amount represented only 8.4% of the total cardiac spillover of DHPG (601±41 pmol/min), providing an explanation for the insignificant nature of the decrease in cardiac spillover of DHPG after desipramine.
Similar to the present results (Figure 4) Figure 6 ).
Sequestration of norepinephrine into vesicles or metabolism to DHPG can be regarded as processes of axoplasmic transmitter loss that must be balanced by transmitter input from neuronal reuptake or vesicular leakage. Thus, subtraction of the reuptake rate (819 pmol/min) from the sum of vesicular sequestration and DHPG production rates (9,693-9,747 pmol/min) indi-cated that the rate of leakage of norepinephrine from storage vesicles was between 8,874 and 8,928 pmol/min ( Figure 6 ). Alternatively, because at rest only 8.4% of the total production of DHPG was from metabolism of recaptured norepinephrine, most (91.6%) from norepinephrine leaking from vesicles, the rate of norepinephrine leakage could be estimated from the reuptake rate to be 8,931 pmol/min (91.6/8.4 819), a result close to that calculated above.
Norepinephrine turnover in the heart can be estimated from the summed rates of loss of norepinephrine and its metabolites into coronary venous plasma. To offset loss from cardiac spillovers of norepinephrine, DHPG, and MHPG, synthesis of norepinephrine in normal subjects at rest was estimated to be 1,004 pmol/min ( Figure 6 ). However, because the contribution to turnover from extraneuronal uptake and metabolism to normetanephrine was not included, this estimate represents the minimal rate of synthesis required to maintain cardiac transmitter stores. A previous study using an open-chest anesthetized dog heart preparation indicated that the contribution of extraneuronal uptake and metabolism to norepinephrine turnover was similar to the contribution of norepinephrine spillover. 33 To estimate the rate of synthesis of dopamine, the cardiac spillovers of dopamine and its metabolites DOPAC and HVA must be considered. Cardiac spillover of HVA could not be detected; that of dopamine is negligibly small, but that of DOPAC indicated that less than 13% of the dopamine produced in the heart escaped vesicular sequestration and further metabolism to norepinephrine ( Figure 6 ). Thus, similar to norepinephrine, vesicular sequestration of dopamine is a highly efficient process, responsible for removing over 87% of the dopamine in the axoplasm. Further comparison of the rate of cardiac DOPA spillover (81 pmol/min) with the minimum rate of dopamine synthesis (1,160 pmol/min) indicated that less than 6.5% of the DOPA produced in the heart by the action of tyrosine hydroxylase escaped further metabolism to spill over into plasma.
Summary
The present report shows how combined measurements of cardiac spillovers of DHPG and norepinephrine allow examination of processes close to or within the sympathetic nerve ending. In particular, the present results have shown that vesicular-axoplasmic exchange of norepinephrine is a dynamic process, contributing importantly to norepinephrine turnover, with a rate at rest of over 100-fold more than that of norepinephrine spillover and over 10-fold more than that of norepinephrine reuptake.
